Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Psoriasis Severity and Endothelial Function
NCT01527097Phase 3Withdrawn
- Start
- Aug 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Atorvastatin with Placebo (2 arms). Primary endpoint: Composite endpoint of improving of psoriatic severity and endothelial function at 12 months. Planned start Aug 2012; status: withdrawn.
02
Drugs
atorvastatin
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT01527097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527097.